FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308121609> ?p ?o ?g. }

• W4308121609 endingPage "5377" @default.
• W4308121609 startingPage "5377" @default.
• W4308121609 abstract "Glioblastoma is the most common histologic type of all gliomas and contributes to 57.3% of all cases. Despite the standard management based on surgical resection and radiotherapy, it is related to poor outcome, with a 5-year relative survival rate below 6.9%. In order to improve the overall outcome for patients, the new therapeutic strategies are needed. Herein, we describe the current state of knowledge on novel targeted therapies in glioblastoma. Based on recent studies, we compared treatment efficacy measured by overall survival and progression-free survival in patients treated with selected potential antitumor drugs. The results of the application of the analyzed inhibitors are highly variable despite the encouraging conclusions of previous preclinical studies. This paper focused on drugs that target major glioblastoma kinases. As far, the results of some BRAF inhibitors are favorable. Vemurafenib demonstrated a long-term efficacy in clinical trials while the combination of dabrafenib and trametinib improves PFS compared with both vemurafenib and dabrafenib alone. There is no evidence that any MEK inhibitor is effective in monotherapy. According to the current state of knowledge, BRAF and MEK inhibition are more advantageous than BRAF inhibitor monotherapy. Moreover, mTOR inhibitors (especially paxalisib) may be considered a particularly important group. Everolimus demonstrated a partial response in a significant proportion of patients when combined with bevacizumab, however its actual role in the treatment is unclear. Neither nintedanib nor pemigatinib were efficient in treatment of GBM. Among the anti-VEGF drugs, bevacizumab monotherapy was a well-tolerated option, significantly associated with anti-GBM activity in patients with recurrent GBM. The efficacy of aflibercept and pazopanib in monotherapy has not been demonstrated. Apatinib has been proven to be effective and tolerable by a single clinical trial, but more research is needed. Lenvatinib is under trial. Finally, promising results from a study with regorafenib may be confirmed by the ongoing randomized AGILE trial. The studies conducted so far have provided a relatively wide range of drugs, which are at least well tolerated and demonstrated some efficacy in the randomized clinical trials. The comprehensive understanding of the molecular biology of gliomas promises to further improve the treatment outcomes of patients." @default.
• W4308121609 created "2022-11-08" @default.
• W4308121609 creator A5004029841 @default.
• W4308121609 creator A5024434194 @default.
• W4308121609 creator A5035807545 @default.
• W4308121609 creator A5042806149 @default.
• W4308121609 creator A5050913534 @default.
• W4308121609 creator A5061832003 @default.
• W4308121609 date "2022-10-31" @default.
• W4308121609 modified "2023-10-05" @default.
• W4308121609 title "New Directions in the Therapy of Glioblastoma" @default.
• W4308121609 cites W1204143572 @default.
• W4308121609 cites W1826437673 @default.
• W4308121609 cites W1846586690 @default.
• W4308121609 cites W1964100609 @default.
• W4308121609 cites W1964588231 @default.
• W4308121609 cites W1965370740 @default.
• W4308121609 cites W1986117263 @default.
• W4308121609 cites W1997304999 @default.
• W4308121609 cites W1998941426 @default.
• W4308121609 cites W2031278548 @default.
• W4308121609 cites W2065455574 @default.
• W4308121609 cites W2073649720 @default.
• W4308121609 cites W2077876620 @default.
• W4308121609 cites W2080515137 @default.
• W4308121609 cites W2084859122 @default.
• W4308121609 cites W2089756110 @default.
• W4308121609 cites W2091621737 @default.
• W4308121609 cites W2097512974 @default.
• W4308121609 cites W2101219622 @default.
• W4308121609 cites W2101844536 @default.
• W4308121609 cites W2102614717 @default.
• W4308121609 cites W2104352635 @default.
• W4308121609 cites W2107731988 @default.
• W4308121609 cites W2109816625 @default.
• W4308121609 cites W2110128697 @default.
• W4308121609 cites W2123178053 @default.
• W4308121609 cites W2128546510 @default.
• W4308121609 cites W2129531694 @default.
• W4308121609 cites W2132697290 @default.
• W4308121609 cites W2135465849 @default.
• W4308121609 cites W2148977460 @default.
• W4308121609 cites W2158125586 @default.
• W4308121609 cites W2158681922 @default.
• W4308121609 cites W2160766792 @default.
• W4308121609 cites W2161190434 @default.
• W4308121609 cites W2162605078 @default.
• W4308121609 cites W2164323018 @default.
• W4308121609 cites W2164753697 @default.
• W4308121609 cites W2165871546 @default.
• W4308121609 cites W2167750533 @default.
• W4308121609 cites W2168199397 @default.
• W4308121609 cites W2170367762 @default.
• W4308121609 cites W219963632 @default.
• W4308121609 cites W2296095373 @default.
• W4308121609 cites W2296457333 @default.
• W4308121609 cites W2366536035 @default.
• W4308121609 cites W2386040222 @default.
• W4308121609 cites W2461628610 @default.
• W4308121609 cites W2526011086 @default.
• W4308121609 cites W2568510637 @default.
• W4308121609 cites W2581248353 @default.
• W4308121609 cites W2584466409 @default.
• W4308121609 cites W2587158245 @default.
• W4308121609 cites W2589486847 @default.
• W4308121609 cites W2590936958 @default.
• W4308121609 cites W2591697035 @default.
• W4308121609 cites W2608462921 @default.
• W4308121609 cites W2621838563 @default.
• W4308121609 cites W2622197960 @default.
• W4308121609 cites W2623739851 @default.
• W4308121609 cites W2732147664 @default.
• W4308121609 cites W2758375389 @default.
• W4308121609 cites W2766040983 @default.
• W4308121609 cites W2768388636 @default.
• W4308121609 cites W2769872337 @default.
• W4308121609 cites W2770221757 @default.
• W4308121609 cites W2778283729 @default.
• W4308121609 cites W2781606447 @default.
• W4308121609 cites W2787049507 @default.
• W4308121609 cites W2798060590 @default.
• W4308121609 cites W2803329568 @default.
• W4308121609 cites W2887387458 @default.
• W4308121609 cites W2888310778 @default.
• W4308121609 cites W2890744696 @default.
• W4308121609 cites W2896001331 @default.
• W4308121609 cites W2897563882 @default.
• W4308121609 cites W2898608732 @default.
• W4308121609 cites W2902935766 @default.
• W4308121609 cites W2903289999 @default.
• W4308121609 cites W2904710333 @default.
• W4308121609 cites W2906329032 @default.
• W4308121609 cites W2912868289 @default.
• W4308121609 cites W2920712387 @default.
• W4308121609 cites W2939800702 @default.
• W4308121609 cites W2948687975 @default.
• W4308121609 cites W2954397531 @default.
• W4308121609 cites W2955562873 @default.

• next